In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Headline
The Food and Drug Administration Oct. 29 issued a proposed rule to update infant formula nutrient requirements, the first such update since 1998. The proposal…
Headline
Extending Medicaid coverage by 12 months following childbirth increased use of postpartum care among mothers with pregnancy complications such as diabetes and…
Headline
The Centers for Disease Control and Prevention issued a reminder Oct. 14 that the declaration supporting the emergency use of COVID-19 in vitro diagnostics…
Headline
A new blog, part of the Keeping Care Close to Home initiative, discusses how connected care networks are essential to sustaining rural maternal care. The blog…
Blog
When the American Hospital Association launched the Keeping Care Close to Home: Innovations in Rural Maternal Health project in 2025, we set out to understand…
Headline
The Department of Health and Human Services Oct. 9 announced the launch of its Newborn Essentials Support Toolkit Program, which, through partnership with the…